Voyager Therapeutics has signed another big pharma partner for its TRACER adeno-associated virus (AAV) vector technology, designed to improve the safety of gene therapies, with Novartis tak
Biogen has made a $15 million investment in digital health company TheraPanacea, which will go towards a project to find digital health tools aimed at neurological diseases.
Roche has formed a decade-long alliance with Recursion Pharma that will focus on using machine learning and "industrialised" drug discovery to find new neuroscience and cancer drugs.
GlaxoSmithKline has formed a five-year partnership with Oxford University to set up a new institute that will apply machine learning and functional genomics to the discovery of new medicine
There’s no doubt that CAR-T therapies have transformed the treatment of many blood cancers, but a risk of secondary malignancies has cast a pall over the class.